Skip to search formSkip to main contentSkip to account menu

everolimus

Known as: SDZ-RAD, 40-O-(2-hydroxyethyl)-rapamycin, 42-O-(2-Hydroxy)ethyl Rapamycin 
A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the… 
National Institutes of Health

Related topics

Related topics

26 relations

Broader (4)

Antineoplastic AgentsImmunosuppressive AgentsPolyenesSirolimus

Narrower (4)

CerticanEC0565RAD 001Zortress
Everolimus:MCnc:Pt:Bld.dot:QnEverolimus:MCnc:Pt:Bld:QnEverolimus:Mass:Pt:Dose:QnIn Blood

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Highly Cited
2014
Highly Cited
2014
Response and acquired resistance to everolimus in anaplastic thyroid cancer.
Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective in treating tumors harboring alterations in… 
Highly Cited
2014
Highly Cited
2014
Treating Epilepsy in Tuberous Sclerosis with Everolimus: Getting Closer
Commentary Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by hamartomas in any organ system… 
Review
2013
Review
2013
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
IntroductionEffective treatments for hormone-receptor-positive (HR+) breast cancer (BC) following relapse/progression on… 
Review
2010
Review
2010
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
BACKGROUND Neurosurgical resection is the standard treatment for subependymal giant-cell astrocytomas in patients with the… 
Highly Cited
2010
Highly Cited
2010
Everolimus Plus Reduced‐Exposure CsA versus Mycophenolic Acid Plus Standard‐Exposure CsA in Renal‐Transplant Recipients
Everolimus allows calcineurin‐inhibitor reduction without loss of efficacy and may improve renal‐transplant outcomes. In a 24… 
Review
2010
Review
2010
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.
RATIONALE Noninfectious pneumonitis is a known class effect of mammalian target of rapamycin (mTOR) inhibitors. OBJECTIVES To… 
Highly Cited
2008
Highly Cited
2008
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.
PURPOSE To identify the optimal regimen and dosage of the oral mammalian target of rapamycin inhibitor everolimus (RAD001… 
Highly Cited
2008
Highly Cited
2008
Investigation of traumatic brain injuries using the next generation of simulated injury monitor (SIMon) finite element head model.
The objective of this study was to investigate potential for traumatic brain injuries (TBI) using a newly developed… 
Review
2004
Review
2004
Clinical Pharmacokinetics of Everolimus
Abstract Everolimus is an immunosuppressive macrolide bearing a stable 2-hydroxy-ethyl chain substitution at position 40 on the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)